The history of sulfonamides began with the 1908 synthesis of the first compound by Paul Gelmo, but their antibacterial properties were discovered in 1932 by Gerhard Domagk at Bayer. This led to the development of the first effective systemic antibacterial drug, a red dye called Prontosil. Although Prontosil was initially a dye, it was later found to be a prodrug that the body converts to the active compound, sulfanilamide. Domagk’s discovery was revolutionary, as sulfonamides were the first synthetic drugs to effectively treat bacterial infections, and he was awarded the 1939 Nobel Prize for his work.
-
1908: The first sulfonamide compound is synthesized by chemistry student Paul Gelmo.
-
1932: Gerhard Domagk at Bayer AG begins testing different sulfonamide compounds for antibacterial effects.
-
1935: Bayer introduces Prontosil, the first commercially available and widely effective synthetic antibacterial drug. It is patented by Josef Klarer and Fritz Mietzsch.
-
1936: French chemist Ernest Fourneau discovers that Prontosil is a prodrug, meaning it is metabolized into the active compound, sulfanilamide, within the body.
-
1939: Domagk receives the Nobel Prize in Physiology or Medicine for his discovery of Prontosil.
-
1940s: Sulfonamides become a crucial part of the war effort in World War II, saving countless lives by treating bacterial infections in wounded soldiers.
-
Post-WWII: The discovery and widespread availability of penicillin gradually leads to a decline in the use of sulfonamides due to concerns about effectiveness and side effects, despite their importance in treating conditions like pneumonia and urinary tract infections.
-
1980s to present: Interest in sulfonamides is revived, particularly with the combination of sulfamethoxazole and trimethoprim for treating infections like Pneumocystis jirovecii pneumonia (PCP) in AIDS patients. Sulfonamides are still widely used today for various conditions.
MBH/AB